Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Clinically significant hypersensitivity to piperazine type drugs (Antepar, Stelazine).
• •Severe uncontrollable diarrhea or vomiting or known malabsorption.
• •Symptomatic hyperlipidemia.
• •Concurrent Medication:
• •Excluded:
• •Other experimental drugs.
• •AZT, ddI, ddC, foscarnet, immunomodulators or other agents with primary antiretroviral activity (exemptions by principal investigator permitted).
• •Patients with the following prior conditions are excluded:
• •History of clinically significant cardiovascular disease or nervous system or muscle disease, including seizures, peripheral neuropathy, dementia, or motor dysfunction.
• •Prior Medication:
• •Excluded:
• •Experimental drugs within 4 weeks prior to study entry.